All entries for: Dermatology

August 5, 2026

Pfizer - New York

Layoffs

New York, NY

10,000+ employees

“Pfizer is adding $2.5 billion in cuts to an ongoing restructuring, with much of the new reduction coming from technology and simplification efforts across the New York pharma’s commercial, R&D and manufacturing functions.

The cuts under Pfizer’s Realigning Our Cost Base Program are expected to save $1 billion, the company announced Aug. 4 in its second-quarter earnings release. Most savings will occur between 2027 and 2029, but not for free: the program carries a one-time cost of $2 billion for digital enablement, implementation and severance.

A company spokesperson declined to give further details on how severance will be paid, whether any jobs will be affected, or what technological changes are planned.”

Disease Area: Antiviral, Cardiology, Dermatology, Gastrointestinal, Immune Diseases, Infectious Diseases, Metabolic Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

July 28, 2026

Incyte Corp

Neutral Outlook

Wilmington, DE

1,001-5,000 employees

In addition, the Inflation Reduction Act of 2022 (the “IRA”) introduced several significant changes to Medicare, including: requiring CMS to negotiate prices for certain high-expenditure, single source Medicare drugs; imposing inflation-based rebates on manufacturers whose prices increase faster than inflation; redesigning the Medicare Part D benefit to cap beneficiary out-of-pocket costs while requiring manufacturers to provide mandatory discounts under the Medicare Part D Manufacturer Discount Program beginning in 2025; and establishing penalties for manufacturers that fail to comply with applicable Medicare Drug Price Negotiation Program requirements.

Disease Area: Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

July 23, 2026

Clinuvel Pharmaceuticals

Layoffs

Melbourne, Victoria

51-200 employees

“As part of a reorganization to focus resources on the U.S. market, CLINUVEL PHARMACEUTICALS will cut its global workforce by 10% to 20%, the company announced Thursday. With 104 employees as of June 15 per an SEC filing, the layoffs could affect as many as 21 people.

The biopharma, which develops therapies for genetic, metabolic and dermatological disorders, will relocate its headquarters from Australia to New York in early 2027 to strengthen regulatory engagement and commercial partnerships. It noted that its late-stage programs, especially in vitiligo, mainly target the U.S. patient population, which it estimates at about 6 million.

CLINUVEL said the workforce reduction realigns operating costs with current revenue and near-term clinical and commercial priorities. It also called the restructuring a prerequisite to accessing deeper, more liquid capital pools in the U.S.”

Disease Area: Dermatology, Rare Disease

Drug Type: Biologic

Source

July 8, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

“In its largest layoff round this year, Novartis is cutting its East Hanover, New Jersey, workforce for a fourth time, letting go of 322 employees and bringing the site’s total to 572. The cuts take effect Oct. 2, per a WARN Act notice.

The first three rounds at the Swiss pharma’s East Hanover site were disclosed in March, April and May, affecting 114, 60 and 76 employees respectively. All are effective this year.

In total, Novartis has announced or disclosed at least 792 job cuts in 2026. In May, the company confirmed to BioSpace it was laying off a select number of staff in its biomedical research arm. That same month, it announced the closure of a production site in Wehr, Germany by the end of 2028, eliminating 220 jobs.”

Disease Area: Cardiology, Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

June 12, 2026

Genentech

Layoffs

South San Francisco, CA

10,000+ employees

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

May 22, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis is continuing to trim its workforce in the U.S., letting go of 76 employees in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs will take effect on Aug. 21.

This will be the third time this year that Novartis downsized its New Jersey operations. The first batch of layoffs was announced in March, affecting 114 employees set to take effect from June 26 through Nov. 27. The second hit came a month later, with 60 jobs projected to be cut from July 24 through Nov. 20.

Novartis earlier this month also announced that it would close down a production site in Germany by the end of 2028, eliminating 220 jobs in the process.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple

Drug Type: Biologic, Small Molecule

Source

May 22, 2026

AbbVie

Layoffs

North Chicago, IL

10,000+ employees

AbbVie’s operations in Irvine, California, will be 85 employees leaner after July 20, with layoffs projected to take place on that date, according to a Worker Adjustment and Retraining Notification (WARN) Act alert.

The pharma has over 40 open posts available in California, including data science and biologics product development listings. A recent BioSpace report found that AbbVie CEO Robert Michael saw a 76% pay bump, with his total compensation package reaching $32.5 million last year as compared to $18.5 million in 2024.

As per BioSpace’s tally, this is the first time AbbVie has announced layoffs this year.

Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

May 15, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis is letting go of “a select number” of employees within its biomedical research organization, a company spokesperson confirmed to BioSpace in an emailed statement.

“Novartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company,” the statement read. “We regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities.”

The cuts are the latest in a series of made or projected layoffs at Novartis this year that in total affect nearly 400 employees. Earlier this month, the Swiss pharma announced plans to shutter a production facility in Wehr, Germany, by the end of 2028. Novartis expects that closure will eliminate 220 jobs. In March and April, the pharma disclosed between two Worker Adjustment and Retraining Notification (WARN) Act notices that it will let go of 174 employees in East Hanover, New Jersey. Of those cuts, layoffs affecting 114 people are effective June 26 through Nov. 27, while those impacting 60 staffers run from July 24 through Nov. 20.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

May 15, 2026

Takeda

Layoffs

Tokyo

10,000+ employees

To cut back on costs, Takeda is rolling out a sweeping “transformation program” that will streamline corporate operations and see some 4,500 employees let go in fiscal year 2026, according to an earnings presentation. That number represents less than 10% of total roles globally and does not reflect hiring plans, a company spokesperson told BioSpace in an emailed response on May 13.

“Right now, we have 2,200 open roles globally and we expect to create new jobs throughout the year, which we are prioritizing filling with internal candidates,” the spokesperson said.

The layoffs will look different across the organization and will be phased according to unique business needs and country requirements, according to the spokesperson. They confirmed that the cuts include an estimated 247 roles in Massachusetts and 387 in other states outlined in a March Worker Adjustment and Retraining Notification (WARN) Act notice.

Disease Area: Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

May 11, 2026

Septerna, Inc.

Neutral Outlook

South San Francisco, CA

51-200 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Dermatology, Endocrinology, Immune Diseases, Metabolic Diseases

Drug Type: Small Molecule

Source